Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
05
2020
accepted:
15
02
2021
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
14
10
2021
Statut:
epublish
Résumé
The prognostic impact of neoadjuvant chemotherapy (NAC) on the receptor expression status in patients with locally advanced breast cancer (LABC) is still not fully understood. We aimed to evaluate the changes in hormone (estrogen and progesterone) receptor (HR) and human epidermal growth factor receptor 2 (HER2) status post-NAC and their correlation with survival. Patients with LABC who have received NAC between 2008 and 2015 and have been followed up till December 2019 at the Oncology Center, King Saud University, KSA were analyzed retrospectively. biomarker analysis of ER, PR & HER2 were done using immunohistochemistry (IHC) and Fluorescent in situ hybridization. Ninety-one patients fulfilled the inclusion criteria. HR status changed in 21(23.1%) patients, with a significant difference between patients with stable receptors and those with any receptor conversion; p = 0.000. Five (5.5%) initially HER2 negative tumors became HER2 positive and 10 (11%) initially HER2 positive tumors became HER2 negative after NAC. The difference in HER2 expression level before and after NAC was not statistically significant (p = 0.302). Univariate analysis relating patients' characteristics and 10-years disease-free survival (DFS) showed only significant correlations with the expressions of ER, PR, and any receptor conversion, (ER and/or PR) p< 0.001, p< 0.001, and p = 0.001; respectively. In the univariate analysis, none of the clinicopathological features showed a significant correlation with the OS except for the molecular subtypes P<0.001. Patients with LABC have significant changes in the ER and PR receptor status following NAC. Post-NAC expressions change of ER and PR (ER and/or PR) are correlated to DFS. Retesting of the hormone receptors should be considered after NAC in Saudi patients with LABC.
Sections du résumé
BACKGROUND
The prognostic impact of neoadjuvant chemotherapy (NAC) on the receptor expression status in patients with locally advanced breast cancer (LABC) is still not fully understood. We aimed to evaluate the changes in hormone (estrogen and progesterone) receptor (HR) and human epidermal growth factor receptor 2 (HER2) status post-NAC and their correlation with survival.
METHODS
Patients with LABC who have received NAC between 2008 and 2015 and have been followed up till December 2019 at the Oncology Center, King Saud University, KSA were analyzed retrospectively. biomarker analysis of ER, PR & HER2 were done using immunohistochemistry (IHC) and Fluorescent in situ hybridization.
RESULTS
Ninety-one patients fulfilled the inclusion criteria. HR status changed in 21(23.1%) patients, with a significant difference between patients with stable receptors and those with any receptor conversion; p = 0.000. Five (5.5%) initially HER2 negative tumors became HER2 positive and 10 (11%) initially HER2 positive tumors became HER2 negative after NAC. The difference in HER2 expression level before and after NAC was not statistically significant (p = 0.302). Univariate analysis relating patients' characteristics and 10-years disease-free survival (DFS) showed only significant correlations with the expressions of ER, PR, and any receptor conversion, (ER and/or PR) p< 0.001, p< 0.001, and p = 0.001; respectively. In the univariate analysis, none of the clinicopathological features showed a significant correlation with the OS except for the molecular subtypes P<0.001.
CONCLUSIONS
Patients with LABC have significant changes in the ER and PR receptor status following NAC. Post-NAC expressions change of ER and PR (ER and/or PR) are correlated to DFS. Retesting of the hormone receptors should be considered after NAC in Saudi patients with LABC.
Identifiants
pubmed: 33667252
doi: 10.1371/journal.pone.0247802
pii: PONE-D-20-15406
pmc: PMC7935307
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Estrogen
0
Receptors, Progesterone
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0247802Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Breast J. 2008 Mar-Apr;14(2):141-6
pubmed: 18248553
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
J Clin Oncol. 2010 Apr 10;28(11):1821-8
pubmed: 20231683
Oncotarget. 2015 Apr 20;6(11):9600-11
pubmed: 25826079
Clin Breast Cancer. 2015 Apr;15(2):153-60
pubmed: 25454687
Virchows Arch. 2005 May;446(5):489-96
pubmed: 15838646
Ann Surg Oncol. 2012 Sep;19(9):3002-11
pubmed: 22437200
Cells. 2020 Dec 09;9(12):
pubmed: 33316954
J Clin Oncol. 2011 Apr 20;29(12):1531-8
pubmed: 21422407
Int J Clin Exp Pathol. 2014 Jun 15;7(7):4086-94
pubmed: 25120787
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
J Clin Oncol. 1996 May;14(5):1718-29
pubmed: 8622093
Br J Cancer. 2005 Jan 17;92(1):147-55
pubmed: 15611798
Cancer Treat Rev. 2011 Oct;37(6):422-30
pubmed: 21177040
Br J Cancer. 2002 Apr 8;86(7):1041-6
pubmed: 11953845
Croat Med J. 2012 Jun;53(3):239-43
pubmed: 22661137
Breast. 2008 Oct;17(5):523-7
pubmed: 18534850
Breast Cancer. 2005;12(4):294-8
pubmed: 16286910
Oncologist. 2007 Jun;12(6):636-43
pubmed: 17602055
Am J Surg. 2009 Oct;198(4):520-5
pubmed: 19800460
Cancer Invest. 2011 Nov;29(9):594-8
pubmed: 22011281
Cancer. 2003 Feb 1;97(3):545-53
pubmed: 12548595
Oncol Lett. 2017 Jul;14(1):337-344
pubmed: 28693173
Cancer Res. 1980 Nov;40(11):4043-7
pubmed: 6451282
J Natl Cancer Inst. 2005 Feb 2;97(3):188-94
pubmed: 15687361
J Clin Invest. 2011 Oct;121(10):3789-96
pubmed: 21965335
J Surg Oncol. 2017 Dec;116(8):1021-1028
pubmed: 28767137
World J Surg Oncol. 2018 Mar 7;16(1):51
pubmed: 29514654
Breast Cancer (Dove Med Press). 2013 Oct 17;5:103-9
pubmed: 24648763
Cancer J. 2002 Nov-Dec;8(6):461-8
pubmed: 12500855
Arch Pathol Lab Med. 2020 May;144(5):545-563
pubmed: 31928354